clinical trial · NCT07179380
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary HypertensionInterstitial Lung DiseaseTreprostinil Palmitil Inhalation PowderPlacebo
brief summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
started
Jan 7, 2026
primary completion
Dec 30, 2028
completion
Dec 30, 2028
last updated
Apr 14, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol